Delcath Systems Inc (DCTH)

[benandemmiboo]

After the financing, it may have same price and about the same amount of shares as pre R/S, but it will also have about 10-15 million in cash, no debt, and full control over patents, along with positive developments for its main product.
There is a reason to think the price should go up where Delcath can at least compare, market-cap wise, with junk biotechs. (That alone would bring stock to about 12 cents.) Right now, it is bottom of the pack, lower than biotechs with unproven products) with a seemingly validated Chemostat product that is still not priced much into the market cap.